Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View

This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics.

In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData's epidemiology forecast.

Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC.

The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in Phase III development, and another seven in Phase II.

Over the past decade, 237 clinical trials have been conducted in PBC. The years with the most studies initiated were 2022 and 2024 with 33 trials each, followed by 2021 with 27 trials.

Over the past decade, acquisitions made up the largest proportion of deals in North America (52%), Europe (38.9%), and the Asia-Pacific (APAC) region (33.3%) transcations.

The consensus from PMR was that PBC diagnosis is largely incidental, with persistent underdiagnosis in primary care driven by lack of awareness and absence of early symptoms and UDCA as the universal first-line therapy, and second-line agents like Iqirvo (elafibranor) and Lyvdelzi (seladelpar lysine), compete for share.

Scope

GlobalData's Diabetic Retinopathy: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.